# A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Clinical trial · Hansoh BioMedical R&D Company

- Archive id: nct:NCT06417008
- Published: 2024-05-16
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06417008
- Source URL: https://clinicaltrials.gov/study/NCT06417008
- Provenance: clinicaltrials

## Abstract

HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of this study is to assess the safety, efficacy, pharmacokinetics and immunogenicity of HS-20117 combined with Aumolertinib in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \\\[Exon 19del\\\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- status: RECRUITING
- phase: PHASE2, PHASE3
- study type: INTERVENTIONAL
- enrollment: 1080
- sponsor: Hansoh BioMedical R&D Company
- conditions: Non-Squamous Non-Small Cell Lung Cancer
- interventions: DRUG: HS-20117; DRUG: Aumolertinib
- start date: 2024-05-28
- start date type: ACTUAL
- primary completion date: 2026-06-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Cancer Immunotherapy](https://space-kitty.com/topics/cancer-immunotherapy)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.